ScienceMed®

Antitumor Activity of s-Triazine Derivatives: A Systematic Review

Oncologia
Imagem de arquivo, ilustrativa — não é do estudo. Linfócito T humano ao microscópio eletrônico de varredura (colorizado). NIAID · CC BY 2.0 · Wikimedia Commons

Revisão sistemáticaNível 1 · Evidência consolidadaMolecules (Basel, Switzerland)23 mai 2023103 citações

Salvar

Resumo original em inglês

O que aconteceu

1,3,5-triazine derivatives, also called s-triazines, are a series of containing-nitrogen heterocyclic compounds that play an important role in anticancer drug design and development. To date, three s-triazine derivatives, including altretamine, gedatolisib, and enasidenib, have already been approved for refractory ovarian cancer, metastatic breast cancer, and leukemia therapy, respectively, demonstrating that the s-triazine core is a useful scaffold for the discovery of novel anticancer drugs. In this review, we mainly focus on s-triazines targeting topoisomerases, tyrosine kinases, phosphoinositide 3-kinases, NADP+-dependent isocitrate dehydrogenases, and cyclin-dependent kinases in diverse signaling pathways, which have been extensively studied. The medicinal chemistry of s-triazine derivatives as anticancer agents was summarized, including discovery, structure optimization, and biological applications. This review will provide a reference to inspire new and original discoveries.

Resumo publicado sob licença CC BY. A tradução para o português ainda não chegou a este estudo.

O estudo original

Antitumor Activity of s-Triazine Derivatives: A Systematic Review

Qiuzi Dai, Qinsheng Sun, Xiaorong Ouyang, Jinyang Liu, Liye Jin, Ahao Liu, Binsheng He, Tingting Fan, Yuyang Jiang

Descritores MeSH

  • Antineoplastic Agents
  • Breast Neoplasms
  • Drug Screening Assays, Antitumor
  • Female
  • Humans
  • Structure-Activity Relationship
  • Triazines
  • Drug Design

Veja também